CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionReturn on equity is -188.4%, lower than 95% of its Biotechnology peers (median -24.5%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.57BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
2.65xvs all stocks
52-Week Change
630.62%vs all stocks
Market Capitalization
1.57BUSDvs all stocks (USD)
Enterprise Value
1.81BUSDvs all stocks (USD)
Forward P/E
-19.03xvs Biotechnology peers
Price to Book (MRQ)
32.61xvs Biotechnology peers
Enterprise to EBITDA
-23.59xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-83.90%vs Biotechnology peers
Return on Equity (TTM)
-188.40%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Aug 8, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-76.90MUSDvs all stocks (USD)
Net Income (TTM)
-75.86MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-59.34MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-31.25MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Aug 8, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-70.66MUSDvs all stocks (USD)
Pre-tax Income
-68.34MUSDFY2025 · Dec 31, 2025Income Tax Expense
1.04MUSDFY2025 · Dec 31, 2025Net Income
-69.38MUSDFY2025 · Dec 31, 2025EBIT
-70.66MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-70.59MUSDFY2025 · Dec 31, 2025Research & Development
58.25MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
12.41MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
2.71MUSDFY2025 · Dec 31, 2025EPS (Basic)
-4.71USDFY2025 · Dec 31, 2025EPS (Diluted)
-4.71USDFY2025 · Dec 31, 2025Basic Shares Outstanding
14.72MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
14.72MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-69.38MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-56.71MUSDFY2025 · Dec 31, 2025Free Cash Flow
-56.83MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
76.96MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-69.38MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
64.00KUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
1.04MUSDFY2025 · Dec 31, 2025Stock-based Compensation
6.26MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-237.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
5.54MUSDFY2025 · Dec 31, 2025Capital Expenditures
-116.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
0.00USDFY2025 · Dec 31, 2025Sale of Investments
36.35MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
36.23MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
0.00USDFY2025 · Dec 31, 2025Other Financing Charges
-7.47MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
67.53MUSDFY2025 · Dec 31, 2025Shares Outstanding
13.91MSharesUpdated Aug 8, 2026Shares Short
2.06MSharesUpdated Aug 8, 2026Short Ratio
2.43daysvs all stocks
Short % of Shares Outstanding
10.13%vs all stocks
% Held by Insiders
2.14%vs all stocks
% Held by Institutions
75.82%vs all stocks
Total Cash (MRQ)
58.22MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.38USDUpdated Aug 8, 2026Total Debt (MRQ)
0.00USDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xvs Biotechnology peers
Current Ratio (MRQ)
2.75xvs Biotechnology peers
Book Value per Share (MRQ)
2.36USDUpdated Aug 8, 2026Total Assets
82.78MUSDvs all stocks (USD)
Total Current Assets
80.59MUSDFY2025 · Dec 31, 2025Total Liabilities
21.79MUSDFY2025 · Dec 31, 2025Total Non-current Assets
2.19MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
1.04MUSDFY2025 · Dec 31, 2025Total Current Liabilities
20.75MUSDFY2025 · Dec 31, 2025Cash
3.28MUSDFY2025 · Dec 31, 2025Cash Equivalents
73.68MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
76.96MUSDFY2025 · Dec 31, 2025Other Short-term Investments
0.00USDFY2025 · Dec 31, 2025Accounts Payable
9.99MUSDFY2025 · Dec 31, 2025Common Stock (Book)
13.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-223.37MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
60.99MUSDvs all stocks (USD)
52-Week Low
9.91USDUpdated Aug 8, 202652-Week High
77.20USDUpdated Aug 8, 202652-Week Change
630.62%vs all stocks
Beta
2.65xvs all stocks
50-Day MA
32.95USDUpdated Aug 8, 2026200-Day MA
26.72USDUpdated Aug 8, 2026Avg 10-Day Volume
3.45MSharesUpdated Aug 8, 2026Avg 30-Day Volume
1.83MSharesUpdated Aug 8, 2026Diluted EPS (TTM)
-4.58USDUpdated Aug 8, 2026Other Income / Expense
-396.00KUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -188.4%, lower than 95% of its Biotechnology peers (median -24.5%)Significant
Return on equity: -1.88Industry median: -0.25Industry P5: -1.55Peers compared: 197
Return on assets is -83.9%, lower than 95% of its Biotechnology peers (median -21.3%)Significant
Return on assets: -0.84Industry median: -0.21Industry P5: -0.74Peers compared: 197
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.1×)Notable
Debt-to-equity: 0.00Industry median: 0.10Industry P5: 0.00Peers compared: 197
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.67
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Market cap is $1.57B, above the global median of $1.15BNotable
Market cap (USD): 1,573,426,562Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Harbin Gloria Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sihuan Pharmaceutical Holdings Group Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Recursion Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Yantai Dongcheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hualan Biological Engineering Inc.
Tier 1ProductionApproval-Gated PipelineRule
Enovis Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Intellia Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Green Thumb Industries Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule
Vir Biotechnology Inc.
Tier 1ProductionApproval-Gated PipelineRule
Maze Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule